Immediate Impact
29 standout
Citing Papers
Catalytic Asymmetric Construction of Chiral Polysubstituted 3-Azabicyclo[3.1.1]heptanes by Copper-Catalyzed Stereoselective Formal [4π+2σ] Cycloaddition
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Daniel Morillo being referenced
A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Daniel Morillo | 138 | 148 | 93 | 27 | 262 | |
| Morten Salomo | 164 | 236 | 189 | 28 | 327 | |
| A Miliani | 138 | 193 | 119 | 23 | 315 | |
| Rainer Boxhammer | 151 | 162 | 76 | 25 | 308 | |
| Natalie Schub | 138 | 163 | 56 | 20 | 284 | |
| Adam Walter‐Croneck | 127 | 169 | 107 | 32 | 269 | |
| Siyang Leng | 111 | 95 | 200 | 30 | 304 | |
| Frauke Ringel | 42 | 60 | 56 | 23 | 280 | |
| Yu Abe | 162 | 94 | 100 | 27 | 313 | |
| Fahad Alsharif | 83 | 126 | 62 | 27 | 314 | |
| Sandra P. Susanibar-Adaniya | 161 | 49 | 114 | 27 | 301 |
All Works
Login with ORCID to disown or claim papers
Loading papers...